References

Akacha, M., Binkowitz, B., Bretz, F., Fritsch, A., Hougaard, P., Jahn-Eimermacher, A., & al., et. (2018). Request for CHMP qualification opinion: Clinically interpretable treatment effect measures based on recurrent event endpoints that allow for efficient statistical analyses. http://www.ema.europa.eu/documents/other/qualification-opinion-treatment-effect-measures-when-using-recurrent-event-endpoints-applicants_en.pdf.

Akacha, M., Bretz, F., Ohlssen, D., Rosenkranz, G., & Schmidli, H. (2017). Estimands and Their Role in Clinical Trials. Statistics in Biopharmaceutical Research, 9(3), 268–271. https://doi.org/10.1080/19466315.2017.1302358

Bebu, I., & Lachin, J. M. (2016). Large sample inference for a win ratio analysis of a composite outcome based on prioritized components. Biostatistics, 17(1), 178–187. https://doi.org/10.1093/biostatistics/kxv032

Bennett, S. (1983). Analysis of survival data by the proportional odds model. Statistics in Medicine, 2(2), 273–277. https://doi.org/10.1002/sim.4780020223

Brunner, E., Vandemeulebroecke, M., & Mütze, T. (2021). Win odds: An adaptation of the win ratio to include ties. Statistics in Medicine, 40(14), 3367–3384. https://doi.org/10.1002/sim.8967

Buyse, M. (2010). Generalized pairwise comparisons of prioritized outcomes in the two-sample problem. Statistics in Medicine, 29(30), 3245–3257. https://doi.org/10.1002/sim.3923

CHMP. (2020). Qualification opinion of clinically interpretable treatment effect measures based on recurrent event endpoints that allow for efficient statistical analyses. https://www.ema.europa.eu/en/documents/other/qualification-opinion-clinically-interpretable-treatment-effect-measures-based-recurrent-event_en.pdf.

Cui, Y., & Huang, B. (2023). WINS: The r WINS package. https://CRAN.R-project.org/package=WINS

Deltuvaite-Thomas, V., Verbeeck, J., Burzykowski, T., Buyse, M., Tournigand, C., Molenberghs, G., & Thas, O. (2022). Generalized pairwise comparisons for censored data: An overview. Biometrical Journal, 65(2). https://doi.org/10.1002/bimj.202100354

Dong, G., Hoaglin, D. C., Huang, B., Cui, Y., Wang, D., Cheng, Y., & Gamalo-Siebers, M. (2023). The stratified win statistics (win ratio, win odds, and net benefit). Pharmaceutical Statistics, 22(4), 748–756. https://doi.org/10.1002/pst.2293

Dong, G., Hoaglin, D. C., Qiu, J., Matsouaka, R. A., Chang, Y.-W., Wang, J., & Vandemeulebroecke, M. (2020). The Win Ratio: On Interpretation and Handling of Ties. Statistics in Biopharmaceutical Research, 12(1), 99–106. https://doi.org/10.1080/19466315.2019.1575279

Dong, G., Huang, B., Chang, Y.-W., Seifu, Y., Song, J., & Hoaglin, D. C. (2020a). The win ratio: Impact of censoring and follow-up time and use with nonproportional hazards. Pharmaceutical Statistics, 19(3), 168–177. https://doi.org/10.1002/pst.1977

Dong, G., Huang, B., Verbeeck, J., Cui, Y., Song, J., Gamalo-Siebers, M., Wang, D., Hoaglin, D. C., Seifu, Y., Mütze, T., & Kolassa, J. (2022). Win statistics (win ratio, win odds, and net benefit) can complement one another to show the strength of the treatment effect on time-to-event outcomes. Pharmaceutical Statistics, 22(1), 20–33. https://doi.org/10.1002/pst.2251

Dong, G., Huang, B., Wang, D., Verbeeck, J., Wang, J., & Hoaglin, D. C. (2021). Adjusting win statistics for dependent censoring. Pharmaceutical Statistics, 20(3), 440–450. https://doi.org/10.1002/pst.2086

Dong, G., Li, D., Ballerstedt, S., & Vandemeulebroecke, M. (2016). A generalized analytic solution to the win ratio to analyze a composite endpoint considering the clinical importance order among components. Pharmaceutical Statistics, 15(5), 430–437. https://doi.org/10.1002/pst.1763

Dong, G., Mao, L., Huang, B., Gamalo-Siebers, M., Wang, J., Yu, G., & Hoaglin, D. C. (2020b). The inverse-probability-of-censoring weighting (IPCW) adjusted win ratio statistic: an unbiased estimator in the presence of independent censoring. Journal of Biopharmaceutical Statistics, 30(5), 882–899. https://doi.org/10.1080/10543406.2020.1757692

Dong, G., Qiu, J., Wang, D., & Vandemeulebroecke, M. (2017). The stratified win ratio. Journal of Biopharmaceutical Statistics, 28(4), 778–796. https://doi.org/10.1080/10543406.2017.1397007

EUnetHTA. (2015). Guidance for industry: Multiple endpoints in clinical trials. https://www.eunethta.eu/wp-content/uploads/2018/01/Endpoints-used-for-Relative-Effectiveness-Assessment-Composite-endpoints_Amended-JA1-Guideline_Final-Nov-2015_0.pdf

Fay, M. P., Brittain, E. H., Shih, J. H., Follmann, D. A., & Gabriel, E. E. (2018). Causal estimands and confidence intervals associated with Wilcoxon-Mann-Whitney tests in randomized experiments. Statistics in Medicine, 37(20), 2923–2937. https://doi.org/10.1002/sim.7799

FDA. (2022). Guidance for industry: Multiple endpoints in clinical trials. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/multiple-endpoints-clinical-trials-guidance-industry

FDA. (2023). Guidance document: Adjusting for covariates in randomized clinical trials for drugs and biological products. US Food and Drug Adminstration. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/adjusting-covariates-randomized-clinical-trials-drugs-and-biological-products

Fine, J. P., & Gray, R. J. (1999). A Proportional Hazards Model for the Subdistribution of a Competing Risk. Journal of the American Statistical Association, 94(446), 496–509. https://doi.org/10.1080/01621459.1999.10474144

Finkelstein, D. M., & Schoenfeld, D. A. (1999). Combining mortality and longitudinal measures in clinical trials. Statistics in Medicine, 18(11), 1341–1354. https://doi.org/10.1002/(sici)1097-0258(19990615)18:11<1341::aid-sim129>3.0.co;2-7

Follmann, D., Fay, M. P., Hamasaki, T., & Evans, S. (2019). Analysis of ordered composite endpoints. Statistics in Medicine, 39(5), 602–616. https://doi.org/10.1002/sim.8431

Freemantle, N., Calvert, M., Wood, J., Eastaugh, J., & Griffin, C. (2003). Composite Outcomes in Randomized Trials. JAMA, 289(19), 2554. https://doi.org/10.1001/jama.289.19.2554

Fritsch, A., Schlömer, P., Mendolia, F., Mütze, T., & Jahn-Eimermacher, A. (2023). Efficiency Comparison of Analysis Methods for Recurrent Event and Time-to-First Event Endpoints in the Presence of Terminal EventsApplication to Clinical Trials in Chronic Heart Failure. Statistics in Biopharmaceutical Research, 15(2), 268–279. https://doi.org/10.1080/19466315.2021.1945488

Gasparyan, S. B., Folkvaljon, F., Bengtsson, O., Buenconsejo, J., & Koch, G. G. (2020). Adjusted win ratio with stratification: Calculation methods and interpretation. Statistical Methods in Medical Research, 30(2), 580–611. https://doi.org/10.1177/0962280220942558

Gasparyan, S. B., Kowalewski, E. K., Folkvaljon, F., Bengtsson, O., Buenconsejo, J., Adler, J., & Koch, G. G. (2021). Power and sample size calculation for the win odds test: application to an ordinal endpoint in COVID-19 trials. Journal of Biopharmaceutical Statistics, 31(6), 765–787. https://doi.org/10.1080/10543406.2021.1968893

Gehan, E. A. (1965). A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika, 52(1-2), 203–224. https://doi.org/10.1093/biomet/52.1-2.203

Ghosh, D., & Lin, D. Y. (2000). Nonparametric Analysis of Recurrent Events and Death. Biometrics, 56(2), 554–562. https://doi.org/10.1111/j.0006-341x.2000.00554.x

Gray, R. J. (1988). A class of K-sample tests for comparing the cumulative incidence of a competing risk. The Annals of Statistics, 16(3). https://doi.org/10.1214/aos/1176350951

ICH. (1998). Statistical principles for clinical trials. London: European Medicines Evaluation Agency.

ICH. (2020). ICH E9 (R1) addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials, step 5. London: European Medicines Evaluation Agency.

Ionan, A. C., Paterniti, M., Mehrotra, D. V., Scott, J., Ratitch, B., Collins, S., Gomatam, S., Nie, L., Rufibach, K., & Bretz, F. (2022). Clinical and Statistical Perspectives on the ICH E9(R1) Estimand Framework Implementation. Statistics in Biopharmaceutical Research, 15(3), 554–559. https://doi.org/10.1080/19466315.2022.2081601

Li, H., Chen, W.-C., Lu, N., Tang, R., & Zhao, Y. (2024). The elusiveness of the win ratio parameter in the presence of missing data. Therapeutic Innovation & Regulatory Science, 1–2.

Lin, D. Y., Wei, L. J., & Ying, Z. (1993). Checking the Cox model with cumulative sums of martingale-based residuals. Biometrika, 80(3), 557–572. https://doi.org/10.1093/biomet/80.3.557

Lu, Y., & Tian, L. (2021). Statistical Considerations for Sequential Analysis of the Restricted Mean Survival Time for Randomized Clinical Trials. Statistics in Biopharmaceutical Research, 13(2), 210–218. https://doi.org/10.1080/19466315.2020.1816491

Luo, X., Huang, B., & Quan, H. (2019). Design and monitoring of survival trials based on restricted mean survival times. Clinical Trials, 16(6), 616–625. https://doi.org/10.1177/1740774519871447

Luo, X., Qiu, J., Bai, S., & Tian, H. (2017). Weighted win loss approach for analyzing prioritized outcomes. Statistics in Medicine, 36(15), 2452–2465. https://doi.org/10.1002/sim.7284

Luo, X., Tian, H., Mohanty, S., & Tsai, W. Y. (2015). An Alternative Approach to Confidence Interval Estimation for the Win Ratio Statistic. Biometrics, 71(1), 139–145. https://doi.org/10.1111/biom.12225

Mao, L. (2018). On causal estimation using U-statistics. Biometrika, 105(1), 215–220. https://doi.org/10.1093/biomet/asx071

Mao, L. (2019). On the Alternative Hypotheses for the Win Ratio. Biometrics, 75(1), 347–351. https://doi.org/10.1111/biom.12954

Mao, L. (2023a). Nonparametric Inference of General While-Alive Estimands for Recurrent Events. Biometrics, 79(3), 1749–1760. https://doi.org/10.1111/biom.13709

Mao, L. (2023b). On restricted mean time in favor of treatment. Biometrics, 79(1), 61–72. https://doi.org/10.1111/biom.13570

Mao, L. (2023c). Power and Sample Size Calculations for the Restricted Mean Time Analysis of Prioritized Composite Endpoints. Statistics in Biopharmaceutical Research, 15(3), 540–548. https://doi.org/10.1080/19466315.2022.2110936

Mao, L. (2023d). Study Design for Restricted Mean Time Analysis of Recurrent Events and Death. Biometrics, 79(4), 3701–3714. https://doi.org/10.1111/biom.13923

Mao, L. (2024). Defining estimand for the win ratio: separate the true effect from censoring. Clinical Trials, In press.

Mao, L., & Kim, K. (2021). Statistical Models for Composite Endpoints of Death and Nonfatal Events: A Review. Statistics in Biopharmaceutical Research, 13(3), 260–269. https://doi.org/10.1080/19466315.2021.1927824

Mao, L., Kim, K., & Li, Y. (2022). On recurrent-event win ratio. Statistical Methods in Medical Research, 31(6), 1120–1134. https://doi.org/10.1177/09622802221084134

Mao, L., Kim, K., & Miao, X. (2022). Sample size formula for general win ratio analysis. Biometrics, 78(3), 1257–1268. https://doi.org/10.1111/biom.13501

Mao, L., & Lin, D. Y. (2016). Semiparametric regression for the weighted composite endpoint of recurrent and terminal events. Biostatistics, 17(2), 390–403. https://doi.org/10.1093/biostatistics/kxv050

Mao, L., & Wang, T. (2021). A class of proportional win-fractions regression models for composite outcomes. Biometrics, 77(4), 1265–1275. https://doi.org/10.1111/biom.13382

Mao, L., & Wang, T. (2024). Dissecting the restricted mean time in favor of treatment. Journal of Biopharmaceutical Statistics, 34(1), 111–126. https://doi.org/10.1080/10543406.2023.2210658

Moertel, C. G., Fleming, T. R., Macdonald, J. S., Haller, D. G., Laurie, J. A., Goodman, P. J., Ungerleider, J. S., Emerson, W. A., Tormey, D. C., Glick, J. H., Veeder, M. H., & Mailliard, J. A. (1990). Levamisole and Fluorouracil for Adjuvant Therapy of Resected Colon Carcinoma. New England Journal of Medicine, 322(6), 352–358. https://doi.org/10.1056/nejm199002083220602

Murphy, S. A., Rossini, A. J., & Vaart, A. W. van der. (1997). Maximum Likelihood Estimation in the Proportional Odds Model. Journal of the American Statistical Association, 92(439), 968–976. https://doi.org/10.1080/01621459.1997.10474051

O’Connor, C. M., Whellan, D. J., Lee, K. L., Keteyian, S. J., Cooper, L. S., Ellis, S. J., Leifer, E. S., Kraus, W. E., Kitzman, D. W., Blumenthal, J. A., Rendall, D. S., Miller, N. H., Fleg, J. L., Schulman, K. A., McKelvie, R. S., Zannad, F., Piña, I. L., & HF-ACTION Investigators, for the. (2009). Efficacy and Safety of Exercise Training in Patients With Chronic Heart Failure. JAMA, 301(14), 1439. https://doi.org/10.1001/jama.2009.454

Oakes, D. (1989). Bivariate Survival Models Induced by Frailties. Journal of the American Statistical Association, 84(406), 487–493. https://doi.org/10.1080/01621459.1989.10478795

Oakes, D. (2016). On the win-ratio statistic in clinical trials with multiple types of event. Biometrika, 103(3), 742–745. https://doi.org/10.1093/biomet/asw026

Péron, J., Buyse, M., Ozenne, B., Roche, L., & Roy, P. (2016). An extension of generalized pairwise comparisons for prioritized outcomes in the presence of censoring. Statistical Methods in Medical Research, 27(4), 1230–1239. https://doi.org/10.1177/0962280216658320

Pocock, S. J., Ariti, C. A., Collier, T. J., & Wang, D. (2012). The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. European Heart Journal, 33(2), 176–182. https://doi.org/10.1093/eurheartj/ehr352

Qu, Y., & Lipkovich, I. (2021). Implementation of ICH E9 (R1): A Few Points Learned During the COVID-19 Pandemic. Therapeutic Innovation & Regulatory Science, 55(5), 984–988. https://doi.org/10.1007/s43441-021-00297-6

Ratitch, B., Bell, J., Mallinckrodt, C., Bartlett, J. W., Goel, N., Molenberghs, G., O’Kelly, M., Singh, P., & Lipkovich, I. (2020). Choosing Estimands in Clinical Trials: Putting the ICH E9(R1) Into Practice. Therapeutic Innovation & Regulatory Science, 54(2), 324–341. https://doi.org/10.1007/s43441-019-00061-x

Redfors, B., Gregson, J., Crowley, A., McAndrew, T., Ben-Yehuda, O., Stone, G. W., & Pocock, S. J. (2020). The win ratio approach for composite endpoints: practical guidance based on previous experience. European Heart Journal, 41(46), 4391–4399. https://doi.org/10.1093/eurheartj/ehaa665

Royston, P., & Parmar, M. K. B. (2011). The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt. Statistics in Medicine, 30(19), 2409–2421. https://doi.org/10.1002/sim.4274

Schmidli, H., Roger, J. H., & Akacha, M. (2023a). Estimands for Recurrent Event Endpoints in the Presence of a Terminal Event. Statistics in Biopharmaceutical Research, 15(2), 238–248. https://doi.org/10.1080/19466315.2021.1895883

Schmidli, H., Roger, J. H., & Akacha, M. (2023b). Rejoinder to Commentaries on “Estimands for Recurrent Event Endpoints in the Presence of a Terminal Event”. Statistics in Biopharmaceutical Research, 15(2), 255–256. https://doi.org/10.1080/19466315.2023.2166098

Seifu, Y., Mt-Isa, S., Duke, K., Gamalo-Siebers, M., Wang, W., Dong, G., & Kolassa, J. (2022). Design of paediatric trials with benefit-risk endpoints using a composite score of adverse events of interest (AEI) and win-statistics. Journal of Biopharmaceutical Statistics, 33(6), 696–707. https://doi.org/10.1080/10543406.2022.2153202

Song, J., Verbeeck, J., Huang, B., Hoaglin, D. C., Gamalo-Siebers, M., Seifu, Y., Wang, D., Cooner, F., & Dong, G. (2022). The win odds: statistical inference and regression. Journal of Biopharmaceutical Statistics, 33(2), 140–150. https://doi.org/10.1080/10543406.2022.2089156

Tian, L., Jin, H., Uno, H., Lu, Y., Huang, B., Anderson, K. M., & Wei, L. (2020). On the empirical choice of the time window for restricted mean survival time. Biometrics, 76(4), 1157–1166. https://doi.org/10.1111/biom.13237

Troendle, J. F., Leifer, E. S., Yang, S., Jeffries, N., Kim, D.-Y., Joo, J., & O’Connor, C. M. (2024). Use of win time for ordered composite endpoints in clinical trials. Statistics in Medicine, 43(10), 1920–1932. https://doi.org/10.1002/sim.10045

Tsiatis, A. A., Davidian, M., Zhang, M., & Lu, X. (2008). Covariate adjustment for two-sample treatment comparisons in randomized clinical trials: A principled yet flexible approach. Statistics in Medicine, 27(23), 4658–4677. https://doi.org/10.1002/sim.3113

Uno, H., & Horiguchi, M. (2023). Ratio and difference of average hazard with survival weight: New measures to quantify survival benefit of new therapy. Statistics in Medicine, 42(7), 936–952. https://doi.org/10.1002/sim.9651

Verbeeck, J., De Backer, M., Verwerft, J., Salvaggio, S., Valgimigli, M., Vranckx, P., Buyse, M., & Brunner, E. (2023). Generalized Pairwise Comparisons to Assess Treatment Effects. Journal of the American College of Cardiology, 82(13), 1360–1372. https://doi.org/10.1016/j.jacc.2023.06.047

Wang, B., Susukida, R., Mojtabai, R., Amin-Esmaeili, M., & Rosenblum, M. (2021). Model-Robust Inference for Clinical Trials that Improve Precision by Stratified Randomization and Covariate Adjustment. Journal of the American Statistical Association, 118(542), 1152–1163. https://doi.org/10.1080/01621459.2021.1981338

Wang, B., Zhou, D., Zhang, J., Kim, Y., Chen, L.-W., Dunnmon, P., Bai, S., Liu, Q., & Ishida, E. (2023). Statistical power considerations in the use of win ratio in cardiovascular outcome trials. Contemporary Clinical Trials, 124, 107040. https://doi.org/10.1016/j.cct.2022.107040

Wang, T., Li, Y., & Qu, Y. (2024). Restricted time win ratio: from estimands to estimation. Statistics in Biopharmaceutical Research, 1–18. https://doi.org/10.1080/19466315.2024.2332675

Wang, T., & Mao, L. (2022). Stratified proportional win-fractions regression analysis. Statistics in Medicine, 41(26), 5305–5318. https://doi.org/10.1002/sim.9570

Wang, T., Zilinskas, R., Li, Y., & Qu, Y. (2023). Missing Data Imputation for a Multivariate Outcome of Mixed Variable Types. Statistics in Biopharmaceutical Research, 15(4), 826–837. https://doi.org/10.1080/19466315.2023.2169753

Wei, J., Mütze, T., Jahn-Eimermacher, A., & Roger, J. (2023). Properties of Two While-Alive Estimands for Recurrent Events and Their Potential Estimators. Statistics in Biopharmaceutical Research, 15(2), 257–267. https://doi.org/10.1080/19466315.2021.1994457

Wu, P., Han, Y., Chen, T., & Tu, X. M. (2013). Causal inference for Mann-Whitney-Wilcoxon rank sum and other nonparametric statistics. Statistics in Medicine, 33(8), 1261–1271. https://doi.org/10.1002/sim.6026

Yang, S., & Troendle, J. (2020). Event-specific win ratios and testing with terminal and non-terminal events. Clinical Trials, 18(2), 180–187. https://doi.org/10.1177/1740774520972408

Yang, S., Troendle, J., Pak, D., & Leifer, E. (2022). Event-specific win ratios for inference with terminal and non-terminal events. Statistics in Medicine, 41(7), 1225–1241. https://doi.org/10.1002/sim.9266

Ye, T., Shao, J., Yi, Y., & Zhao, Q. (2023). Toward Better Practice of Covariate Adjustment in Analyzing Randomized Clinical Trials. Journal of the American Statistical Association, 118(544), 2370–2382. https://doi.org/10.1080/01621459.2022.2049278

Yu, R. X., & Ganju, J. (2022). Sample size formula for a win ratio endpoint. Statistics in Medicine, 41(6), 950–963. https://doi.org/10.1002/sim.9297

Zhou, T. J., LaValley, M. P., Nelson, K. P., Cabral, H. J., & Massaro, J. M. (2022). Calculating power for the Finkelstein and Schoenfeld test statistic for a composite endpoint with two components. Statistics in Medicine, 41(17), 3321–3335. https://doi.org/10.1002/sim.9419

Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Inzucchi, S. E. (2015). Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine, 373(22), 2117–2128. https://doi.org/10.1056/nejmoa1504720